Search studies using keywords
5,026 Studies in the database containing data with -log p ≥ 0 (showing 201-220)
Pages: << 11 12 13 14 15 16 17 18 19 20 >>
No data sets (in No Studies) added to Browser
Identifier Name Phenotype(s) Total p-values Related citationsAdd data sets to Browser Related data
HGVST4837 plus GWAS of Conotruncal heart defects 
  • Conotruncal heart defects with normally related great vessels in 22q.11.2 deletion syndrome
  • Conotruncal heart defects with normally related great vessels
  • Conotruncal heart defects with normally related great vessels (without 22q.11.2 deletion syndrome)
46
HGVST4818 plus GWAS of Parkinson's disease 
  • Parkinson's disease motor subtype (tremor to postural instability/gait difficulty score ratio)
  • Parkinson's disease motor subtype (tremor dominant vs postural instability/gait difficulty)
38
HGVST4819 plus GWAS of Dichlorodiphenyldichloroethylene 
  • DDT metabolite (p,p'-DDE levels)
1
HGVST4820 plus GWAS of Narcolepsy 
  • Narcolepsy with cataplexy
6
HGVST4821 plus GWAS of Anthropometric traits 
  • Waist-to-hip ratio adjusted for BMI
  • Height
  • Waist-hip ratio
  • Weight
94
HGVST4822 plus GWAS of Coronary artery aneurysm 
  • Kawasaki disease
  • Coronary artery aneurysm in Kawasaki disease
14
HGVST4823 plus GWAS of Rotator cuff injury 
  • Rotator cuff injury
1
HGVST4824 plus GWAS of Thrombosis 
  • Thrombosis in response to liver transplant
11
HGVST4825 plus GWAS of Adipose morphology 
  • Adipose morphology
30
HGVST4826 plus GWAS of Body composition 
  • Visceral adipose tissue mass
  • Leg fat mass
  • Trunk total mass
  • Arm total mass
  • Android fat mass
  • Leg total mass
  • Body fat distribution (trunk fat ratio)
  • Gynoid bone mass
  • Android bone mass
  • Trunk bone mineral content
  • Leg lean mass
  • Gynoid lean mass
  • Arm bone mineral content
  • Android total mass
  • Visceral adipose tissue volume
  • Android fat/gynoid fat ratio
  • Trunk fat/peripheral fat ratio
  • Arm fat mass
  • Gynoid fat mass
  • Trunk fat mass
  • Trunk lean mass
26
HGVST4816 plus GWAS of Alzheimer's disease 
  • Brain amyloid deposition
16
HGVST4817 plus GWAS of Education, socioeconomic status and brain phenome 
  • Subjective wellbeing conditioned on self-rated math ability (multi-trait conditioning and joint analysis)
  • Neuroticism conditioned on Townsend deprivation index (multi-trait conditioning and joint analysis)
  • Subjective wellbeing conditioned on cognitive performance (multi-trait conditioning and joint analysis)
  • Subjective wellbeing conditioned on average household income before tax (multi-trait conditioning and joint analysis)
  • Subjective wellbeing conditioned on highest math class (multi-trait conditioning and joint analysis)
  • Neuroticism conditioned on cognitive performance (multi-trait conditioning and joint analysis)
  • Neuroticism conditioned on average household income before tax (multi-trait conditioning and joint analysis)
  • Subjective wellbeing conditioned on Townsend deprivation index (multi-trait conditioning and joint analysis)
  • Neuroticism conditioned on educational attainment (multi-trait conditioning and joint analysis)
  • Subjective wellbeing conditioned on educational attainment (multi-trait conditioning and joint analysis)
  • Neuroticism conditioned on self-rated math ability (multi-trait conditioning and joint analysis)
  • Neuroticism conditioned on highest math class (multi-trait conditioning and joint analysis)
499
HGVST4812 plus GWAS of Response to anticancer drugs 
  • Response to nintedanib
  • Response to arsenic trioxide
  • Response to trametinib
  • Response to vinblastine
  • Response to tivantinib
  • Response to epirubicin
  • Response to erlotinib
  • Response to oxaliplatin
  • Response to hydroxyurea
  • Response to vemurafenib
  • Response to fluoro-deoxyuridine
  • Response to platinum-based chemotherapy (carboplatin)
  • Response to vinorelbine
  • Response to taxane treatment (docetaxel)
  • Response to dovitinib
  • Response to cladaribine
  • Response to paclitaxel and epirubicin
  • Response to vandetanib
  • Response to temozolomide
  • Response to paclitaxel
  • Response to cytidine analogues (gemcitabine)
51
HGVST4813 plus GWAS of Brain-derived neurotrophic factor 
  • Brain-derived neurotrophic factor levels
7
HGVST4814 plus GWAS of Various traits 
  • Essential hypertension (time to event)
  • Cataract (time to event)
  • Cardiac dysrhythmias (time to event)
  • Asthma (time to event)
  • Coronary atherosclerosis (time to event)
  • Type 2 diabetes (time to event)
  • Hyperlipidemia (time to event)
  • Osteoarthrosis (time to event)
55
HGVST4815 plus GWAS of Various traits 
  • Chronic hepatitis B infection
  • Meniere's disease
  • Brain tumor
  • Cirrhosis
  • Endometrial cancer
  • Epilepsy
  • Hyperthyroidism
  • Asthma
  • HDL cholesterol
  • Systemic lupus erythematosus
  • Medication use (adrenergics, inhalants)
  • Medication use (diuretics)
  • Chronic sinusitis
  • Mean arterial pressure
  • Prostate cancer
  • Medication use (drugs used in diabetes)
  • Medication use (opioids)
  • Contact dermatitis
  • Triglycerides
  • Cardiac valvular disease
  • Insomnia
  • LDL cholesterol
  • Medication use (antithrombotic agents)
  • Medication use (antidepressants)
  • Schizophrenia
  • Chronic bronchitis
  • Glucose levels
  • Mean corpuscular hemoglobin
  • Ulcerative colitis
  • Iron deficiency anemia
  • Atrial fibrillation/atrial flutter
  • Hemoglobin A1c levels
  • Ovarian cyst
  • Myocardial infarction
  • Aplastic anemia
  • Urticaria
  • Type 1 diabetes
  • Dysentery
  • Weight
  • Skin cancer
  • Cervical cancer
  • Glaucoma
  • Medication use (glucocorticoids)
  • Serum alkaline phosphatase levels
  • Stevens-Johnson syndrome
  • Aortic aneurysm
  • Lymphocyte counts
  • Psoriasis vulgaris
  • Neutrophil count
  • Mean corpuscular hemoglobin concentration
  • Retinitis pigmentosa
  • Peripheral artery disease
  • Gastric cancer
  • Serum uric acid levels
  • Typhoid fever
  • Polymyositis
  • Parkinson's disease
  • Medication use (drugs affecting bone structure and mineralization)
  • Keloid
  • Acute glomerulonephritis
  • Medication use (antiglaucoma preparations and miotics)
  • Zoster infection
  • Medication use (agents acting on the renin-angiotensin system)
  • Ringworm
  • Interstitial lung disease
  • Serum total protein level
  • Acute pancreatitis
  • Allergic rhinitis
  • Medication use (anti-inflammatory and antirheumatic products, non-steroids)
  • Lung cancer
  • Ischemic stroke
  • Sleep apnea syndrome
  • Esophageal cancer
  • Medication use (antihistamines for systemic use)
  • Medication use (calcium channel blockers)
  • Cystitis
  • Atopic dermatitis
  • Thyroid cancer
  • Sarcoidosis
  • Pneumothorax
  • Ventricular arrhythmia
  • Blood urea nitrogen levels
  • Nephrotic syndrome
  • Goiter
  • Chronic renal failure
  • C-reactive protein
  • White blood cell count
  • Medication use (HMG CoA reductase inhibitors)
  • Monocyte count
  • Pyelonephritis
  • Unstable angina pectoris
  • Hepatic cancer
  • Varicose veins
  • Intracerebral hemorrhage
  • Spinal canal stenosis
  • Medication use (thyroid preparations)
  • Aspartate aminotransferase levels
  • Gastroesophageal reflux disease
  • Hematocrit
  • Medication use (immunosuppressants)
  • Chronic obstructive pulmonary disease
  • Eosinophil counts
  • Serum albumin levels
  • Subarachnoid hemorrhage
  • Chronic heart failure
  • Bronchitis
  • Angina pectoris
  • Type 2 diabetes
  • Bronchiectasis
  • Cholelithiasis
  • Mastopathy
  • Uterine fibroids
  • Alanine aminotransferase levels
  • Pulse pressure
  • Juvenile rheumatoid arthritis
  • Autoimmune hepatitis
  • Constipation
  • Medication use (antimigraine preparations)
  • Diastolic blood pressure
  • Hypertrophic cardiomyopathy
  • Rheumatoid arthritis
  • Medication use (anilides)
  • Graves' disease
  • Gastric ulcer
  • Gastric polyp
  • Platelet count
  • Uterine prolapse
  • Inguinal hernia
  • Medication use (beta blocking agents)
  • Chronic glomerulonephritis
  • Chronic pancreatitis
  • Depression
  • Hypothyroidism
  • Substance dependence
  • Iritis
  • Pediatric asthma
  • Colorectal cancer
  • Back pain
  • Medication use (antihypertensives)
  • Esophageal varix
  • Hashimoto thyroiditis
  • Carpal tunnel syndrome
  • Uveitis
  • Hemoglobin
  • Retinal detachment
  • Pulmonary fibrosis
  • Neuropathic bladder
  • Malignant lymphoma
  • Height
  • Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease)
  • Hepatic bile duct cancer
  • Pancreatic cancer
  • Pulmonary tuberculosis
  • Hearing loss, difficulty in hearing
  • Systolic blood pressure
  • Sjögren's syndrome
  • Gamma glutamyl transpeptidase
  • Nasal polyps
  • Medication use (vasodilators used in cardiac diseases)
  • Diabetic nephropathy
  • Cerebral aneurysm
  • Chronic hepatitis C infection
  • IgA nephropathy
  • Bell's palsy
  • Pollinosis
  • Basophil count
  • Mean corpuscular volume
  • Stable angina pectoris
  • Urolithiasis
  • Pneumonia
  • Body mass index
  • Total bilirubin levels
  • Endometriosis
  • Osteoporosis
  • Total cholesterol levels
  • Colon polyp
  • Cataracts
  • Gall bladder polyp
  • Calcium levels
  • Breast cancer
  • Cholecystitis
  • Medication use (salicylic acid and derivatives)
  • Serum creatinine levels
  • Red blood cell count
  • Unruptured cerebral aneurysm
  • Metal allergy
17,713
HGVST4798 plus GWAS of Smoking behaviours 
  • Anxiety
  • Anxiety x maternal smoking during pregnancy interaction
  • Depression
  • Depression x maternal smoking during pregnancy interaction
17
HGVST4799 plus GWAS of Frozen shoulder 
  • Frozen shoulder
5
HGVST4800 plus GWAS of Neurofibromatosis type 1 
  • Café-au-lait macule number in neurofibromatosis type1
2
HGVST4801 plus GWAS of IgG N-glycosylation 
  • IgG bisecting N-acetyl glucosamine phenotypes
  • IgG N-glycosylation phenotypes
3